JP2017525955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525955A5 JP2017525955A5 JP2017506291A JP2017506291A JP2017525955A5 JP 2017525955 A5 JP2017525955 A5 JP 2017525955A5 JP 2017506291 A JP2017506291 A JP 2017506291A JP 2017506291 A JP2017506291 A JP 2017506291A JP 2017525955 A5 JP2017525955 A5 JP 2017525955A5
- Authority
- JP
- Japan
- Prior art keywords
- pkd
- patient
- cyclin
- level
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033031P | 2014-08-04 | 2014-08-04 | |
| US62/033,031 | 2014-08-04 | ||
| PCT/US2015/043497 WO2016022500A2 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113693A Division JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525955A JP2017525955A (ja) | 2017-09-07 |
| JP2017525955A5 true JP2017525955A5 (enExample) | 2018-09-13 |
| JP6730252B2 JP6730252B2 (ja) | 2020-07-29 |
Family
ID=54035292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506291A Active JP6730252B2 (ja) | 2014-08-04 | 2015-08-03 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| JP2020113693A Active JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113693A Active JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10871495B2 (enExample) |
| EP (1) | EP3177932B1 (enExample) |
| JP (2) | JP6730252B2 (enExample) |
| KR (1) | KR20170033436A (enExample) |
| CN (1) | CN106716136B (enExample) |
| AU (1) | AU2015301278A1 (enExample) |
| BR (1) | BR112017002003A2 (enExample) |
| CO (1) | CO2017001596A2 (enExample) |
| MX (1) | MX2017001648A (enExample) |
| RU (1) | RU2017106891A (enExample) |
| SG (1) | SG11201700290SA (enExample) |
| WO (1) | WO2016022500A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895963B2 (ja) | 2015-11-18 | 2021-06-30 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE402257T1 (de) | 1999-05-24 | 2008-08-15 | Avi Biopharma Inc | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit |
| CA2574709A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| WO2010141862A2 (en) | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| ES2606140T3 (es) | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| US10478446B2 (en) | 2012-07-03 | 2019-11-19 | Fondazione Centro San Raffaele Office Of Biotechnology Transfer | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2015
- 2015-08-03 RU RU2017106891A patent/RU2017106891A/ru not_active Application Discontinuation
- 2015-08-03 JP JP2017506291A patent/JP6730252B2/ja active Active
- 2015-08-03 EP EP15757363.5A patent/EP3177932B1/en active Active
- 2015-08-03 WO PCT/US2015/043497 patent/WO2016022500A2/en not_active Ceased
- 2015-08-03 CN CN201580053081.4A patent/CN106716136B/zh active Active
- 2015-08-03 AU AU2015301278A patent/AU2015301278A1/en not_active Abandoned
- 2015-08-03 SG SG11201700290SA patent/SG11201700290SA/en unknown
- 2015-08-03 KR KR1020177005740A patent/KR20170033436A/ko not_active Withdrawn
- 2015-08-03 MX MX2017001648A patent/MX2017001648A/es unknown
- 2015-08-03 BR BR112017002003A patent/BR112017002003A2/pt not_active Application Discontinuation
- 2015-08-03 US US15/501,496 patent/US10871495B2/en active Active
-
2017
- 2017-02-17 CO CONC2017/0001596A patent/CO2017001596A2/es unknown
-
2020
- 2020-07-01 JP JP2020113693A patent/JP7005695B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Negoita et al. | PNPLA3 variant M148 causes resistance to starvation‐mediated lipid droplet autophagy in human hepatocytes | |
| Janzic et al. | PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung | |
| Leung et al. | Evidence for the existence of triple‐negative variants in the MCF‐7 breast cancer cell population | |
| Alves et al. | PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex | |
| JP2016536303A5 (enExample) | ||
| Amajoyi et al. | Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens | |
| Kang et al. | Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer | |
| JP2016528914A5 (enExample) | ||
| Fogelman et al. | Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? | |
| JP6860919B2 (ja) | 間葉系ｋｒａｓ変異型がん治療剤 | |
| JP2019502902A5 (enExample) | ||
| RU2017106891A (ru) | Биомаркеры поликистозной болезни почек и пути их применения | |
| Brown et al. | Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development | |
| WO2017087409A1 (en) | Biomarker of polycystic kidney disease and uses thereof | |
| Ochiai et al. | Cerebral phaeohyphomycosis: case report | |
| Mirna et al. | Autoimmune myocarditis is not associated with left ventricular systolic dysfunction | |
| Park et al. | Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor | |
| CN102648921A (zh) | 一种治疗非小细胞肺癌的组合药物 | |
| Pikunov et al. | Personalization of mathematical models of human atrial action potential | |
| US20040186117A1 (en) | Marker | |
| Eathiraj et al. | Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751 | |
| Moody | Overcoming Resistance to Trastuzumab in HER2-Amplified Breast Cancers | |
| Otero et al. | Morphological analysis of CDC2 and glycogen synthase kinase 3β phosphorylation as markers of G2→ M transition in glioma | |
| Noro et al. | Bowen's disease with high telomerase activity | |
| 柯仰謦 et al. | Serum and Pleural Fluid Procalcitonin for Discriminating Complicated Non-Purulent from Uncomplicated Parapneumonic Effusions |